Wockhardt to sell Crawford's skin gel in India

Wockhardt has signed an in-licencing agreement with Crawford Healthcare of UK to market Viticolor, a skin camouflage gel for topical application by vitiligo patients.

According to a release issued by Wockhardt to the BSE today, Vitiligo, popularly called leucoderma, is a skin disorder that affects 3-4% of the Indian population.

The licencing deal follows the launch of Vitix, a patented product from LSI of UK, for the treatment of vitiligo in the Indian market this week.

"Viticolor will complement Vitix and further strengthen our Indian dermatology portfolio," Wockhardt chairman Habil Khorakiwala said. "We bring to India new products that have proved their effectiveness in the Europe and USA."